Genzyme Revises Fabrazyme Phase IV Proposal In Bid For April Approval

Genzyme's proposal for completing its Phase IV Fabrazyme study is the kind of innovative drug development proposal that FDA Commissioner McClellan is encouraging, Genzyme CEO Henri Termeer suggested during a March 5 conference call